Literature DB >> 27737491

Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.

Timothy L Frankel1, Efsevia Vakiani2, Hari Nathan1, Ronald P DeMatteo3, T Peter Kingham3, Peter J Allen3, William R Jarnagin3, Nancy E Kemeny4, David B Solit4, Michael I D'Angelica3.   

Abstract

BACKGROUND: In the past 3 decades, a better understanding of gene mutations and their role in carcinogenesis has led to improvement in our ability to treat patients with metastatic disease. The objective of the current study was to determine whether the location of a driver mutation within an affected gene impacts the biology of metastatic colorectal cancer.
METHODS: DNA was collected from 165 randomly selected specimens of patients who underwent margin-negative resection of colorectal liver metastases with curative intent. Sequenom analysis and Sanger sequencing were used to evaluate mutations in K/NRAS, PIK3CA, BRAF, and TP53.
RESULTS: BRAF mutation was associated with early recurrence and death, whereas no impact of TP53 or PIK3CA mutation was identified. Although K/NRAS mutation was associated with worse survival in this cohort, this difference was no longer evident when those who had received anti-EGFR therapy were excluded. When stratifying patients according to the exon on which K/NRAS was mutated, there were dramatic differences in both survival and pathologic features. Exon 4 mutations were associated with large, solitary metastases occurring at long disease-free intervals compared with exon 3 mutations, which presented with small, numerous lesions. Patients who had exon 4 mutations recurred infrequently and had significantly longer survival compared with those who had wild type or other mutations.
CONCLUSIONS: By using this model of curative-intent, margin-negative resection in patients at high risk of recurrence, the authors were able to establish a link between mutation location within the K/NRAS gene and the biology of metastatic colorectal cancer. Cancer 2017;123:568-575.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  colorectal metastases; hepatectomy; rat sarcoma (RAS) mutation; surgery; v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutation

Mesh:

Substances:

Year:  2016        PMID: 27737491      PMCID: PMC5477980          DOI: 10.1002/cncr.30351

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  23 in total

1.  The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

Authors:  A Fariña-Sarasqueta; G van Lijnschoten; E Moerland; G-J Creemers; V E P P Lemmens; H J T Rutten; A J C van den Brule
Journal:  Ann Oncol       Date:  2010-05-25       Impact factor: 32.976

2.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Murielle Mauer; Erik Tanis; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet Oncol       Date:  2013-10-11       Impact factor: 41.316

3.  Colorectal cancer statistics, 2014.

Authors:  Rebecca Siegel; Carol Desantis; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-03-17       Impact factor: 508.702

4.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

5.  Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Authors:  Manickam Janakiraman; Efsevia Vakiani; Zhaoshi Zeng; Christine A Pratilas; Barry S Taylor; Dhananjay Chitale; Ensar Halilovic; Manda Wilson; Kety Huberman; Julio Cezar Ricarte Filho; Yogindra Persaud; Douglas A Levine; James A Fagin; Suresh C Jhanwar; John M Mariadason; Alex Lash; Marc Ladanyi; Leonard B Saltz; Adriana Heguy; Philip B Paty; David B Solit
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

6.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

7.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

8.  Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.

Authors:  Georgios Karagkounis; Michael S Torbenson; Hubert D Daniel; Nilofer S Azad; Luis A Diaz; Ross C Donehower; Kenzo Hirose; Nita Ahuja; Timothy M Pawlik; Michael A Choti
Journal:  Cancer       Date:  2013-09-19       Impact factor: 6.860

9.  A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients.

Authors:  M Span; P T Moerkerk; A F De Goeij; J W Arends
Journal:  Int J Cancer       Date:  1996-06-21       Impact factor: 7.396

10.  Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Authors:  Carsten Bokemeyer; Igor Bondarenko; Anatoly Makhson; Joerg T Hartmann; Jorge Aparicio; Filippo de Braud; Serban Donea; Heinz Ludwig; Gunter Schuch; Christopher Stroh; Anja H Loos; Angela Zubel; Piotr Koralewski
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

View more
  15 in total

1.  Mutation Status of RAS, TP53, and SMAD4 is Superior to Mutation Status of RAS Alone for Predicting Prognosis after Resection of Colorectal Liver Metastases.

Authors:  Yoshikuni Kawaguchi; Scott Kopetz; Timothy E Newhook; Mario De Bellis; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Jean-Nicolas Vauthey
Journal:  Clin Cancer Res       Date:  2019-06-20       Impact factor: 12.531

2.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Authors:  Georgios Antonios Margonis; Stefan Buettner; Nikolaos Andreatos; Yuhree Kim; Doris Wagner; Kazunari Sasaki; Andrea Beer; Christoph Schwarz; Inger Marie Løes; Maria Smolle; Carsten Kamphues; Jin He; Timothy M Pawlik; Klaus Kaczirek; George Poultsides; Per Eystein Lønning; John L Cameron; Richard A Burkhart; Armin Gerger; Federico N Aucejo; Martin E Kreis; Christopher L Wolfgang; Matthew J Weiss
Journal:  JAMA Surg       Date:  2018-07-18       Impact factor: 14.766

3.  ASO Author Reflections: Characterizing the Impact of RAS Mutation Location on Outcomes for Colorectal Liver Metastases.

Authors:  Lily V Saadat; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2020-07-28       Impact factor: 5.344

Review 4.  Gene mutation and surgical technique: Suggestion or more?

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Jean-Nicolas Vauthey
Journal:  Surg Oncol       Date:  2019-07-18       Impact factor: 3.279

5.  Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy.

Authors:  Raja R Narayan; Jashodeep Datta; Debra A Goldman; Victoria G Aveson; Henry S Walch; Francisco Sanchez-Vega; Mithat Gönen; Vinod P Balachandran; Jeffrey A Drebin; William R Jarnagin; T Peter Kingham; Alice C Wei; Nikolaus Schultz; Nancy E Kemeny; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2022-07-27       Impact factor: 4.339

6.  KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations.

Authors:  Pim B Olthof; Stefan Buettner; Nikolaos Andreatos; Jane Wang; Inger Marie Løes; Doris Wagner; Kazunari Sasaki; Andrea Macher-Beer; Carsten Kamphues; Ioannis Pozios; Hendrik Seeliger; Daisuke Morioka; Katsunori Imai; Klaus Kaczirek; Timothy M Pawlik; George Poultsides; Richard Burkhart; Itaru Endo; Hideo Baba; Peter Kornprat; Federico N Aucejo; Per Eystein Lønning; Katharina Beyer; Matthew J Weiss; Christopher L Wolfgang; Martin E Kreis; Georgios A Margonis
Journal:  Br J Surg       Date:  2022-08-16       Impact factor: 11.122

7.  Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases.

Authors:  Lily V Saadat; Thomas Boerner; Debra A Goldman; Mithat Gonen; Timothy L Frankel; Efsevia Vakiani; T Peter Kingham; William R Jarnagin; Alice C Wei; Kevin C Soares; David B Solit; Michael I D'Angelica
Journal:  Ann Surg Oncol       Date:  2020-07-18       Impact factor: 5.344

8.  Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells.

Authors:  Jenny Lazarus; Morgan D Oneka; Souptik Barua; Tomasz Maj; Mirna Perusina Lanfranca; Lawrence Delrosario; Lei Sun; J Joshua Smith; Michael I D'Angelica; Jinru Shia; Jiayun M Fang; Jiaqi Shi; Marina Pasca Di Magliano; Weiping Zou; Arvind Rao; Timothy L Frankel
Journal:  Ann Surg Oncol       Date:  2019-06-27       Impact factor: 4.339

9.  Association of genomic profiles and survival in early onset and screening-age colorectal cancer patients with liver metastases resected over 15 years.

Authors:  Raja R Narayan; Victoria G Aveson; Joanne F Chou; Henry S Walch; Francisco Sanchez-Vega; Gustavo Dos Santos Fernandes; Vinod P Balachandran; Michael I D'Angelica; Jeffrey A Drebin; William R Jarnagin; Alice C Wei; Andrea Cercek; Mithat Gönen; Nikolaus Schultz; T Peter Kingham
Journal:  J Surg Oncol       Date:  2022-01-23       Impact factor: 2.885

Review 10.  Molecular Determinants and Other Factors to Guide Selection of Patients for Hepatic Resection of Metastatic Colorectal Cancer.

Authors:  Thomas M Diehl; Daniel E Abbott
Journal:  Curr Treat Options Oncol       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.